Evidence map›Paper›PMID 38902509›Full record

ArticleJournal of human hypertension2025

Impact of COVID-19 on the management of hypertension: a perspective on disease severity, service use patterns and expenditures from Ghana's health insurance claims data.

Ama Pokuaa Fenny, Evans Otieku, Samuel Owusu Achiaw, Bernard Okoe Boye, Francis Asenso-Boadi, Vivian Addo-Cobbiah, Mariam Musah

Abstract read
In one paragraph

Article in Journal of human hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ama Pokuaa FennyInstitute of Statistical, Social, and Economic Research (ISSER), University of Ghana, Accra, Ghana.ORCID http://orcid.org/0000-0001-9367-1265
Evans OtiekuInstitute of Statistical, Social, and Economic Research (ISSER), University of Ghana, Accra, Ghana.ORCID http://orcid.org/0000-0002-6809-5160
Samuel Owusu AchiawHealth Economics and Health Technology Assessment, School of Health and Wellbeing, University of Glasgow, Scotland, United Kingdom. samuel.owusuachiaw@glasgow.ac.uk.ORCID http://orcid.org/0009-0000-5711-7240
Bernard Okoe BoyeNational Health Insurance Authority, Accra, Ghana.
Francis Asenso-BoadiNational Health Insurance Authority, Accra, Ghana.
Vivian Addo-CobbiahNational Health Insurance Authority, Accra, Ghana.
Mariam MusahNational Health Insurance Authority, Accra, Ghana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension is a leading cause of morbidity in Ghana and other sub-Saharan African countries, but management has historically suffered from the fragility of health systems in these countries. This has been exacerbated by the COVID-19 pandemic and its associated measures. Our study examines and quantifies the effect of the pandemic on the management of hypertension in Ghana by determining changes in disease severity and presentation, as well as changes in health service use patterns and expenditures. We used cross-sectional data to perform an impact evaluation of COVID-19 on hypertension management before and during the pandemic. We employed statistical tests including t-tests, z-tests, and exact Poisson tests to estimate and compare hypertension episode intensity and related claim expenditures before and during the pandemic using medical claims data from Ghana's National Health Insurance Authority database. The study duration includes a 12-month reference/pre-pandemic period (March 2019-February 2020) relative to the target/pandemic period (March 2020-February 2021). We observed that although there was a 20% reduction in the number of hypertension claimants in the pandemic year, there was an increase in hypertension severity as measured by the number of hypertension episodes per claimant. There was also an 18.64% or $22.88 (95% CI: $21-$25, p = 0.01042) increase in the average cost per hypertension claimant in the pandemic year. The increase in episodes per claimant had the largest financial impact on the average cost per claimant. The findings from our studies are relevant for future policymaking and strategy implementation for hypertension control in Ghana.

Indexed as

COVID-19Health ExpendituresHypertensionAdultCross-Sectional StudiesFemaleGhanaHumansInsurance, HealthMaleMiddle AgedSARS-CoV-2Severity of Illness Index

Identifiers

PMID38902509
PMCPMC11867968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.